A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, placebo-controlled, multi-center phase II clinical
study conducted in China to compare the efficacy and safety of two different dose groups of
AK3280 in IPF patients compared to the placebo control group.